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Cell cycleIn order to investigate the cell death-inducing effects of rotenone, a plant extract commonly used as a
mitochondrial complex I inhibitor, we studied cancer cell lines with different genetic backgrounds. Rotenone
inhibits cell growth through the induction of cell death and cell cycle arrest, associated with the development
of mitotic catastrophe. The cell death inducer staurosporine potentiates the inhibition of cell growth by
rotenone in a dose-dependent synergistic manner. The tumor suppressor p53 is involved in rotenone-induced
cell death, since the drug treatment results in increased expression, phosphorylation and nuclear localization
of the protein. The evaluation of the effects of rotenone on a p53-deﬁcient cell line revealed that although not
required for the promotion of mitotic catastrophe, functional p53 appears to be essential for the extensive cell
death that occurs afterwards. Our results suggest that mitotic slippage also occurs subsequently to the
rotenone-induced mitotic arrest and cells treated with the drug for a longer period become senescent.
Treatment of mtDNA-depleted cells with rotenone induces cell death and cell cycle arrest as in cells
containing wild-type mtDNA, but not formation of reactive oxygen species. This suggests that the effects of
rotenone are not dependent from the production of reactive oxygen species. This work highlights themultiple
effects of rotenone in cancer cells related to its action as an anti-mitotic drug.A, mitochondrial DNA; DMSO,
hydrorhodamine 123; X-gal, 5-
4′,6-diamidino-2-phenylindole;
mbrane potential; CI, combina-
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In recent years, the highly sophistication of the mechanisms of
programmed cell death which guard the organism against unwanted
and potentially harmful cells has become evident. The Nomenclature
Committee on Cell Death proposed recently uniﬁed criteria for the
deﬁnition of cell death and of its different morphologies [1].
Nevertheless, one may ﬁnd several terms to deﬁne different (or not
so different) ways a cell has to die. The balance between cell division
and cell death is of supreme importance for the development and
maintenance of multicellular organisms. Deregulation of this balancecan lead to pathological conditions, like cancer, neurodegenerative
and immune system disorders [2].
One of the cell death processes is mitotic catastrophe. There is not
a deﬁnitive accepted classiﬁcation of mitotic catastrophe and its
signiﬁcance is still under debate but, currently, the concept refers to a
series of events that result from premature or inadequate entry of
cells into mitosis and represent an intermediate stage between a
prolonged mitotic arrest and the set off of cell death [3]. It can be
triggered either by chemical or physical stresses, namely, by drugs
that disturb the stability of microtubules [3,4]. The molecular players
involved in mitotic catastrophe are another matter of investigation.
Rotenone is a plant compound derived from the Leguminosae
family used primarily as a mitochondrial complex I inhibitor. It
induces cell death in several types of cells through the generation of
reactive oxygen species (ROS) [5–7]. ROS formation is considered
crucial, since treatment with antioxidants could abolish rotenone-
induced cell death [6,7]. Yet, it was recently shown that complex I
inhibition is not enough to explain the rotenone effect [8,9] and earlier
studies showed that rotenone has another point of attack within the
cells, the mitotic spindle [10]. Later work described that rotenone
inhibits the assembly of the mitotic spindle by direct binding to
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of rotenone remain elusive. Since compounds that inhibit the spindle
assembly are inducers of mitotic catastrophe, it is reasonable to
presume that rotenone can be such an inducer. Furthermore, studies
in animal models of different forms of cancer demonstrated that
rotenone possesses in vivo anticancer properties [14–17].
This prompted us to further investigate the effects of rotenone in
cancer cells with different genetic backgrounds. In this work we show
that rotenone induces mitotic catastrophe, mitotic slippage, cell death
and cellular senescence in cancer cells and acts by two independent
pathways. Our results also emphasize the involvement of p53 on the
action of rotenone.
2. Materials and methods
2.1. Cell culture, reagents and antibodies
TPC-1 and 8505-C cells were maintained in RPMI-1640 medium
supplementedwith 10% fetal bovine serum, 100U/ml penicillin, 100 μg/
ml streptomycin and 1.25 μg/ml amphotericin B (all from Invitrogen).
143B ρ0 and CMPBR3 cells were maintained in DMEM (Invitrogen)
supplemented with 50 μg/ml uridine (Sigma-Aldrich), 10% fetal bovine
serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 1.25 μg/ml
amphotericin B. The 143B ρ0 cell line is derived from the parental
osteosarcoma cell line 143B after depletion of mitochondrial DNA
(mtDNA) using herpes simplex virus [18]. The CMPBR3 cybrid cell line
was obtained through the fusion of 143B ρ0 cells with platelets from a
healthy individual, as in reference [19]. All cell lines were kept at 37 °C
and5%CO2. For the treatmentswith thedrugs, cellswere seeded and left
to adhere for approximately 24 h.Afterwards, themediumwas replaced
by fresh medium supplemented with the desired concentrations of the
drugs. Stock solutions of rotenone and staurosporine were prepared in
dimethyl sulfoxide (DMSO) at 50 and 10 mM, respectively. DMSO was
used in all experiments as the vehicle (control).
Rotenone, sulphorhodamine B, propidium iodide, dihydroethi-
dium (DHE) and dihydrorhodamine 123 (DHR123) were purchased
from Sigma-Aldrich, DMSO from AppliChem, staurosporine from LC
Laboratories, mounting medium with 4′,6-diamidino-2-phenylindole
(DAPI) from Vector Laboratories, CMXRos (MitoTracker Red) and
rhodamine-phalloidin from Molecular Probes, nonyl acridine orange
from PromoKine, 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside
(X-gal) from NZYTech and RNase A from Fermentas. The following
antibodies were employed: p53 (clone DO-1) (Oncogene Science),
phospho-p53 (Serine 15) (Cell Signaling Technology), SSBP1
(Abnova), OPA1 (BD Biosciences), cytochrome c and complex V
subunit α (MitoSciences) and actin (Santa Cruz Biotechnology).
2.2. Analysis of cell growth
For the sulphorhodamine B assay, cells were ﬁxed with 10%
trichloroacetic acid and stained with 0.1% sulphorhodamine B. The
plates were read in a microplate reader (Bio-Rad) at 560 nm.
Triplicate wells per condition were evaluated in each experiment.
For cell cycle analysis, cells were ﬁxed with ice-cold 70% ethanol for at
least 4 h and, after washing with PBS, stained with a solution
containing 5 μg/ml propidium iodide and 100 μg/ml RNase A. Flow
cytometry was performed in a Epics XL-MCL (Beckman-Coulter) and
the results were analyzed using FlowJo software (Tree Star).
The β-galactosidase assay was carried out as previously described
[20]. Phase-contrast and β-galactosidase micrographs of cells were
taken using a CKX41 (Olympus) inverted microscope.
2.3. Fluorescence microscopy
For observation of nuclei, cells were incubated with 0.075 M KCl
(individual chromosomes can be microscopically identiﬁed andexamined in much greater detail by incubating cells with a hypotonic
solution), washedwith PBS, ﬁxed (with a 3:1mixture ofmethanol and
acetic acid at 4 °C) and stained with DAPI. For staining of F-actin, cells
growing in coverslips were ﬁxed with 4% paraformaldehyde, washed
with PBS, permeabilized with 0.2% Triton X-100 and incubated with
phalloidin-rhodamine diluted 1:40 in PBS for 20 min.
For immunostaining for p53, cells were ﬁxed and permeabilized,
incubated 1 h with blocking buffer (5% normal rabbit serum and 0.3%
Triton X-100 in PBS), 1 h with the primary anti-p53 (DO-1) antibody
(1:40 dilution in 10% BSA+0.3% Triton X-100 in PBS), washed (PBS–
0.5% Tween-20–0.05% BSA) and 1 h with the secondary rabbit anti-
mouse antibody conjugated with ﬂuorescein isothiocyanate (FITC)
(Dako).
The cytochrome c release assay was performed according to the
protocol provided by the manufacturer (MitoSciences). For observa-
tion and analysis, the Axio Imager 2 microscope and the AxioVision LE
software (Zeiss) were used.2.4. Western blotting
Whole lysates of cells were obtained ﬁrst by incubation with RIPA
buffer (50 mM Tris–HCl+1% NP-40+150 mM NaCl+2 mM EDTA,
ph 7.5), a protease inhibitor cocktail (Roche Applied Science) and a
phosphatase inhibitor cocktail (Sigma-Aldrich), followed by centrifu-
gation (14000 rpm, 15 min, 4 °C) and collection of the supernatant.
The lysates were separated by SDS-PAGE and transferred to a
nitrocellulose membrane. The membrane was blocked for 1 h using
a 5% non-fat dry milk or bovine serum albumin in PBS–0.5% Tween-20
solution and incubated with the appropriate primary and secondary
antibodies. The protein bands were detected by chemiluminescence
and X-ray ﬁlm exposure (GE Healthcare).2.5. Analysis of mitochondrial parameters
For evaluation of the production of ROS or mitochondrial
membrane potential (ΔΨm), 5 μM DHE/10 μM DHR123 or 250 nM
CMXRos, respectively, was added to the culture medium for 30 min.
Then, cells were detached, washed two times and resuspended in PBS.
For analysis of the mitochondrial mass, cells were ﬁrst detached,
washed two times and incubated in PBS containing 5 μM nonyl
acridine orange. Samples were analyzed by ﬂow cytometry.
For inspection of mitochondrial morphology, cells growing in
coverslips were incubated with 250 nM CMXRos for 30 min at 37 °C,
ﬁxed with 4% paraformaldehyde, washed twice in PBS and observed
by ﬂuorescence microscopy.2.6. Statistical analysis
For quantiﬁcation of synergy two measurements were employed –
the combination index (CI) and the dose reduction index (DRI) [21] –
using CalcuSyn software (Biosoft). The calculation is based on the
median-effect equation derived from the mass-action law. Brieﬂy, the
median-effect equation describes dose-effect relationships, allows
the construction of the median-effect plot and provides parameters
for the calculation of CI and DRI.When two ormore drugs are combined
and the CI is calculated, CIb1, =1, and N1 indicates synergism, additive
effect, and antagonism, respectively. The DRI measures howmany folds
the dose of each drug in a synergistic combination may be reduced to a
given effect level; the greater DRI value indicates a greater dose
reduction [21]. The remaining statistical analysis of the data was
performed using SPSS 13.0 (SPSS Inc.) by the non-parametric Mann–
Whitney test, for comparisons between two groups. P-valuesb0.05
were considered to be statistically signiﬁcant.
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3.1. Rotenone inhibits the growth of cancer cells and induces cell death,
cell cycle arrest, mitotic catastrophe and cellular senescence
Treatment of TPC-1 cells for 24 h with rotenone results in growth
inhibition, as demonstrated in Supplemental Fig. 1A by phase-contrast
micrographs of the cells. This growth inhibition occurred in a dose-
dependent manner (Supplemental Fig. 1B). The calculated median-
effect dose of the drug or IC50 is 26 μM (data not shown). We analyzed
the cell cycle of TPC-1 cells treated for 24 h with increasing concentra-
tions of rotenone. Fig. 1A shows two representative histograms of the
DNA content of TPC-1 cells treatedwith a control orwith 5 μMrotenone
and quantiﬁcation of the data for the various concentrations tested are
represented in Fig. 1B. Rotenone induces cell death, represented by the
fraction of sub-G1 cells (15.78% for 5 μM rotenone vs. 2.86% for the
control; P=0.006), and also cell cycle arrest, showed by the increase of
the percentage of cells with 4 N DNA content, typical of the G2 and M
phases of the cycle (72.38% for 5 μMrotenone vs. 31.83% for the control;
P=0.006). Thereby, rotenone-induced growth inhibition of TPC-1 cells
can be explained by the induction of death and cell cycle arrest.
Evaluation of the nuclear morphology of TPC-1 cells by ﬂuorescence
microscopy shows that rotenone induces mitotic catastrophe (Fig. 1C).
Scoring of the presence of interphase-like nuclei, mitotic ﬁgures,
aberrant nuclei and clusters of nuclei typical of mitotic catastrophe
(Fig. 1D) denotes a signiﬁcant alteration in all the types of nuclei scored,
including an increase in the number of mitotic ﬁgures (20.18% for 5 μM
rotenonevs. 1.22% for the control; P=0.034 at 24 h) and in thepresence
of syncytia of nuclei resembling those characteristic of mitotic
catastrophe (12.71% for 5 μM rotenone vs. 0% for the control;
P=0.019 at 24 h). TPC-1 cells treated with rotenone for 5 days display
a senescent-like phenotype [22], with a higher size, ﬂattened aspect,
numerous vacuoles and foci of heterochromatin (Fig. 2A). Increased
expression of β-galactosidase (Fig. 2B and C; 14.41% for 5 μM rotenone
vs. 0.18% for the control; P=0.004) supports the observation that
cells become senescent after prolonged exposure to rotenone. Staining
of F-actinwithphalloidin revealedoverexpressionof theﬁlaments and a
considerable increase in cell size (Fig. 2D).
3.2. Involvement of p53 in rotenone-induced cell death
Since p53 is a molecule frequently responsive to cell stress,
particularly cell cycle insults, we tested if rotenone was altering itsFig. 1. Rotenone induces cell death, cell cycle arrest and mitotic catastrophe. (A) Represent
treated with a control (vehicle) (upper panel) or with rotenone (lower panel). (B) Quantiﬁc
drug. (C) Nuclear morphology of 5 μM rotenone-treated cells was assessed by staining with
mitotic ﬁgure; scale bar: 10 μm. (D) Stained nuclei were counted and classiﬁed in four group
based on theirmorphological features. All treatments in this ﬁgure were 24 h long. Data is rep
mean±standard error of mean (SEM). *, Pb0.05; **, Pb0.01.state. Western blot analysis revealed that rotenone induces almost a
two-fold increase in the levels of p53 (Fig. 3A and B; P=0.037). In
control-treated cells, p53 was located in the nucleus and dispersed in
the cytoplasm (Fig. 3C). Conversely, in rotenone-treated cells, p53 was
almost exclusively within the nucleus, including mitotic catastrophe-
like nuclei (Fig. 3C). Phosphorylation of p53 at its serine 15 residue is a
key step during the p53 activation process [23,24]. Rotenone-treated
TPC-1 cells evidenced an increase in the phosphorylation of p53 in
serine 15 (Fig. 3D). Therefore, rotenone induces a nuclear accumulation
of p53 togetherwith an increase in the levels of the protein and possibly
its activation, since its phosphorylation at serine 15 was enhanced by
rotenone. We also studied the expression of the cyclin-dependent
kinase inhibitor p21, which is a p53 target gene that regulates cell cycle
progression at G1 [25,26]. Treatment with rotenone leads to an increase
in the expression of p21 (Fig. 3E).We did not detect alterations in other
molecules tested byWestern blot, speciﬁcally Chk2, Bax, XIAP and cyclin
D1 (data not shown).
To further study the involvement of p53, we analyzed the outcome
of the treatment with rotenone in 8505-C cells. These cells harbor a
point mutation at the DNA-binding domain of TP53 that translates to
the substitution Arg248Gly [27], leading to a non-functional protein
[28]. The basal cell cycle proﬁle of TPC-1 and 8505-C cells is similar
(Supplemental Fig. 2). The cell cycle of 8505-C cells after 24 h of
treatment with 5 μM rotenone is arrested as in TPC-1 cells, as
demonstrated by the percentage of cells with a 4 N DNA content
(80.75% for 5 μM rotenone vs. 35.28% for the control; P=0.05)
(Fig. 4A and C). Analysis of the nuclear morphology of rotenone-
treated 8505-C cells also revealed the presence ofmitotic catastrophe-
like clusters (Fig. 4B).
It is currently accepted that mitotic catastrophe is a biological state
that precedes cell death [3]. Thereby, we tested if there is induction of
cell death after the mitotic catastrophe state induced by the drug. As
depicted in Fig. 4C andD, in TPC-1 cells, therewas a dramatic increase in
thepercentage of hypodiploid cells from24 to48 hof treatment (15.78%
at 24 h vs. 57.70% at 48 h; P=0.009) and a decrease in the percentage of
cells with a DNA content typical of G2/M (72.38% at 24 h vs. 18.48% at
48 h; P=0.009). In contrast, p53-mutant 8505-C cells remain arrested
in the cell cycle after 48 h of treatment and undergo death to a lesser
extent than TPC-1 cells (Fig. 4D; TPC-1 vs. 8505-C cells, P=0.009 for
sub-G1 cells and P=0.008 for G2/M cells). Taken together, these results
suggest that a functional p53, although not required for the rotenone-
induced cell cycle arrest and mitotic catastrophe, plays a role in the
extensive cell death that occurs afterwards.ative histograms of the cell cycle analysis by propidium iodide staining of DNA of cells
ation of the data for experiments like the one in (A) for different concentrations of the
DAPI; the bracket indicates a mitotic catastrophe-like cluster and the arrow points to a
s (mitotic ﬁgures, interphase-like nuclei, clusters/mitotic catastrophe-like and aberrant)
resentative of at least three independent experiments. Data shown in (B) represents the
Fig. 2. Long rotenone treatments induce cellular senescence in TPC-1 cells. (A) Phase-
contrast micrographs of rotenone (ROT)-treated TPC-1 cells; scale bar: 30 μm. The
expression of β-galactosidase was evaluated by staining cells treated with rotenone
with X-gal (B; scale bar: 50 μm) and by calculating the ratio of positive cells/total
number of cells (C). (D) The F-actin ﬁlaments of rotenone-treated cells were stained
with phalloidin-rhodamine; scale bar: 10 μm. The cells were exposed to rotenone for
5 days (after 3 days of treatment the above alterations were already observable). Data is
representative of at least three independent experiments. Data shown in (C) represents
the mean±SEM. **, Pb0.01.
Fig. 3. Rotenone increases the expression, phosphorylation of serine 15 and nuclear
accumulation of p53 in TPC-1 cells. (A)Whole lysates of cells treatedwith rotenone (ROT)
were immunoblotted for p53 and quantiﬁcation of data (B) was determined by relative
intensity (normalized to actin). (C) Cells treated with rotenone were stained for p53 (left
column and green in the right column) andwith DAPI for nuclei (middle column and blue
in the right column); scale bar: 10 μm. (D–G)Whole lysates of cells treatedwith rotenone
were immunoblotted for p53phospho-serine 15(D) andp21 (E). The rotenone treatments
in thisﬁgure correspond to a 24 hperiod. Immunoblotting against actin served as a loading
control. Data is representative of at least three independent experiments. Data shown
in (B) represents the mean±SEM. *, Pb0.05.
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to TPC-1, in 8505-C cells p53 is already located in the nucleus even
without rotenone treatment (Supplemental Fig. 3). 8505-C also undergo
cellular senescence after prolonged treatment with rotenone, as
evidenced by typical morphological alterations (Supplemental Fig. 4A)
and by a signiﬁcant increase in the number of β-galactosidase-positive
cells (2.21% for 5 μM rotenone vs. 0.13% for the control; P=0.001;
Supplemental Fig. 4B and C). However, the percentage of positive cells
is signiﬁcantly higher in TPC-1 than in the 8505-C cell line (14.41% for
TPC-1 cells vs. 2.21% for 8505-C cells; P=0.021). These results indicate
that p53 is also important for the senescence effect of rotenone.
3.3. Rotenone-induced cell death and cell cycle arrest is independent
from the mitochondrial production of ROS
Since oxidative stress induced by rotenone was advanced to be
required to trigger cell death [6,7], we evaluated the formation of ROS
in rotenone-treated TPC-1 cells. Using DHE (for superoxide detec-
tion), the production of ROS showed a signiﬁcant increase both at 6 h
(Fig. 5A and C; 1.25-fold with 5 μM rotenone; P=0.037), and at 24 h
(Fig. 5B and C; 2.12-fold with 5 μM rotenone; P=0.037), in a dose-
dependent manner. This effect was not cell type-speciﬁc, since 8505-C
and HEK293 cells were also stimulated to produce ROS (Supplemental
Fig. 5A and B). Detection of ROS with DHR 123 (detects hydrogen
peroxide, peroxonitrite and hypoclorous acid) provided similar
results (Supplemental Fig. 5C–E).
On the other hand, we checked ROS production in 143B ρ0 cells
(depleted of mtDNA) and in CMPBR3 cells (obtained by fusing the
previous cell line with mitochondria from platelets harboring wild-
type mtDNA). The results showed a remarkable increase in ROS
formation in CMPBR3 cells upon rotenone treatment (Fig. 5D and F;about 2.5-fold with 5 μM rotenone; P=0.028), but not in 143B ρ0 cells
(Fig. 5E and F; 1,16-fold with 5 μM rotenone; P=0.487).
Analysis of the cell cycle in 143B ρ0 and CMPBR3 cells treated with
5 μM rotenone for 24 h show that both cell lines displayed a
signiﬁcant increase in the percentage of dead cells (Fig. 5G and H;
23.16% for 5 μM rotenone vs. 3.01% for the control in CMPBR3 cells,
P=0.018; 17.53% for 5 μM rotenone vs. 1.70% for the control in 143 B
ρ0 cells, P=0.028) and in the percentage of cells in G2/M (64.80% for
5 μM rotenone vs. 34.73% for the control in CMPBR3 cells, P=0.021;
53.49% for 5 μM rotenone vs. 27.37% for the control in 143B ρ0 cells,
P=0.034), similarly to the results obtained with TPC-1 and 8505-C
cells. Thus, it appears that cell death and cell cycle arrest induced by
rotenone is independent from themitochondrial production of ROS, at
least in this model. In addition, the fact that 143B cells harbor a point
mutation at the DNA-binding domain of TP53 that translates to the
substitution Arg156Pro [29], leading to a non-functional protein [28],
further corroborates that a functional p53 is not required for the
rotenone-induced cell cycle arrest.
3.4. Treatment with rotenone leads to alterations in ΔΨm, biogenesis
and morphology
We assessed mitochondrial function in TPC-1 cells treated with
rotenone by estimation of different parameters. A dual effect on the
ΔΨmwas observed (Fig. 6A and B). There is a fraction of cells with loss
of ΔΨm (21.25% for 5 μM rotenone vs. control; P=0.014) and a
Fig. 4. Comparison of the rotenone effects in 8505-C and TPC-1 cells. (A) Quantiﬁcation
of data regarding the cell cycle analysis of 8505-C cells by DNA staining with propidium
iodide after a 24 h treatment with 5 μM rotenone. (B) Nuclear morphology of control
(vehicle)-treated (upper panel) or 5 μM rotenone-treated 8505-C cells was assessed by
staining with DAPI; scale bar: 10 μm. (C and D) Comparison of the cell cycle of TPC-1
and 8505-C cell lines upon treatment with 5 μM rotenone for 24 h (C) or 48 h (D). Data
is representative of at least three independent experiments. Data shown in (A), (C) and
(D) represents the mean±SEM. *, Pb0.05; **, Pb0.01.
Fig. 5. Rotenone-induced cell death and cell cycle arrest is independent from the
mitochondrial production of ROS. (A–F) The production of superoxide was measured
using dihydroethidium as a probe; (A) and (B) are representative ﬂow cytometry
histograms of TPC-1 cells after treatment with rotenone (ROT) and quantiﬁcation of the
data is presented in (C); (D) and (E) are representative ﬂow cytometry histograms of
CMPBR3 (D) and 143B ρ0 (E) cells after treatment with rotenone for 24 h and
quantiﬁcation of the data is presented in (F). In the histograms presented in (A), (B),
(D) and (E), the gray areas correspond to control (vehicle) and the white areas
represent treatment with 5 μM rotenone. (G and H) Cell cycle analysis of CMPBR3 (G)
and 143B ρ0 (H) cells by staining with propidium iodide after treatment with control
(vehicle) or 5 μM rotenone for 24 h. Data is representative of at least three independent
experiments. Data shown in (C), (F), (G) and (H) represents the mean±SEM. *, Pb0.05.
496 A.P. Gonçalves et al. / Biochimica et Biophysica Acta 1813 (2011) 492–499second population of cells with gain of ΔΨm (7.82% for 5 μM rotenone
vs. control; P=0.014) after treatment with rotenone for 24 h. The
population of cells with loss of ΔΨm likely corresponds to those that
are in the process of cell death. The observed hyperpolarization may
result from an increase in mitochondrial mass [30]. In fact, there is a
signiﬁcant 1.5-fold increase in the number of mitochondria (Fig. 6C
and D; P=0.037), suggesting that the drug is stimulating mitochon-
drial biogenesis. Concordantly, we observed an increase in the
expression of SSBP1 (Fig. 6E), a protein that is upregulated during
mitochondrial biogenesis [31]. Thus, the gain of ΔΨm may be a
consequence of the increase in the number of mitochondria. Rotenone
treatment also leads to the presence of cells with a giant nucleus
surrounded by a massive network of fused mitochondria (Fig. 6G).
This correlates with an increase in the expression of the pro-fusion
protein OPA1 (Fig. 6F). Integrity of mitochondria seems to be
maintained since we did not observe release of cytochrome c to the
cytoplasm (Supplemental Fig. 6).
The growth of HEK293 cells, which are derived from non-neoplastic
embryonic kidney tissue, is also inhibited by rotenone and the other
effects described above for TPC-1 cells, such as cell cycle arrest followed
by massive cell death induction, increased expression of p53 and p21
and production of ROS are also observed (data not shown).
3.5. Rotenone and staurosporine act synergistically in inhibiting the
growth of thyroid cancer cells in a dose-dependent manner
Synergistic combinations of drugs represent a good strategy to treat
diseases, namely cancer, because they offer several advantages such as
increasing the efﬁcacy of the treatment, decreasing the dose of the
compounds and slowing down the development of drug resistance [21].
Hence, we decided to evaluate whether rotenone could interact
synergistically with staurosporine, a potent cell death inducer, as
observed recently in the ﬁlamentous fungus Neurospora crassa [9]. In
fact, there is an increase in the percentage of inhibition of cell growthwhen the drugswere combined vs. either drug used alone (Fig. 7A). The
median-effect dose of the 1:1000 (staurosporine:rotenone) combina-
tion was 2 nM/μM, meaning a more powerful effect when compared
with the median-effect doses of 23 nM and 26 μM, for staurosporine or
rotenone alone, respectively) (data not shown). To quantify the
synergistic interaction between the drugs we used the combination
index (CI), which is based on themedian-effect equation and according
which there is synergy when CIb1 [21]. As depicted in Fig. 7B, despite
the presence of 4 points with CIN1, there is a dose-dependent tendency
tohave experimental points falling into theCIb1 region, as illustratedby
the trend linepresented in thegraph.Another indexcalculatedusing the
same data, the dose reduction index (DRI), further supports our
conclusions. DRI is a measure of how many folds the dose of each
drug in a synergistic combinationmay be reduced at a given effect level
comparedwith the doses of eachdrug alone [21]. In this case the greater
DRI (DRIN1) value indicates a greater dose reduction for a given
therapeutic effect [21]. TheDRI calculations (Fig. 7C) for almost all doses
of the drugs are greater than 1.
4. Discussion
A deregulation in the normal processes of cell death and cell cycle
is a common feature of cancer cells [32]. Rotenone was previously
Fig. 6. Rotenone leads to alterations in mitochondrial transmembrane potential, biogenesis and morphology of TPC-1 cells. The mitochondrial membrane potential was determined
by incubating cells with CMXRos followed by analysis through ﬂow cytometry histograms (A) and quantiﬁcation of the data (B). The mitochondrial mass was assessed by staining
cells with nonyl acridine orange followed by analysis through ﬂow cytometry histograms (C) and quantiﬁcation of the data (D). In the histograms presented in (A) and (C), the gray
areas correspond to control (vehicle) and the white areas represent treatment with 5 μM rotenone. Whole lysates of cells treated with the indicated concentrations of rotenone
(ROT) were immunoblotted against SSBP1 (E) and OPA1 (F); in (F), the arrow head points to the mature form of OPA1. (G) The morphology of mitochondria was evaluated by
microscopy after treatment of cells with 5 μM rotenone and incubation with CMXRos (left column and red in the right column) and staining with DAPI for nuclei (middle column and
blue in the right column); scale bar: 10 μm. Data is representative of at least three independent experiments. Data shown in (B) and (D) represents the mean±SEM. *, Pb0.05
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death, both in vitro and in vivo [5–7,14–17,33]. Here we show that
rotenone-induced inhibition of the growth of cancer cells is
potentiated by the death inducer staurosporine in a dose-dependent
manner. A similar synergistic effect of this drug combination was
observed in cells of the ﬁlamentous fungus Neurospora crassa [9].
Because the administration of drugs to cells usually elicit collateral
toxic effects, a strategy to minimize them could be decreasing the
dose of the drug applied and this may be achieved by using drug
combinations as we report. Future experiments are required in order
to evaluate the possible translation of the results to in vivo models.
Since rotenone is an inhibitor of respiratory chain complex I [6],
we evaluated its effect on mitochondria. The mitochondrial networkFig. 7. Staurosporine and rotenone have a synergistic effect against the growth of TPC-1 cell
treatment, for the indicated concentrations of staurosporine, rotenone or the combination of
reduction index (C) using the software CalcuSyn; in (B) the crosses correspond to experime
Data is representative of at least three independent experiments.morphology was modiﬁed but the organelles seemed intact and we
did not observe release of cytochrome c. As expected, a signiﬁcant
percentage of the cells lost their ΔΨm. Yet, other cells exhibited an
increase of ΔΨm, which may be explained by some stimulation of
mitochondrial biogenesis by rotenone. The observed higher number
of mitochondria may account for the increase in the potential per cell,
as already proposed [30]. It was proposed recently that p53 regulates
mitochondrial biogenesis and mtDNA copy number [34,35], in line
with our ﬁndings that the effects of rotenone involve p53. Rotenone
treatment also increased ROS production. Nevertheless, ROS do not
appear to be essential for rotenone-induced cell death in our model.
Cells with depleted mtDNA are not stimulated to produce ROS, but
become arrested in the cell cycle and undergo death to a similars. (A) Growth inhibition was determined by the sulphorhodamine B assay, after 24 h of
both drugs. Synergy was evaluated according to the combination index (B) and the dose
ntal values and the curve is a trend line; in (C) the dashed line corresponds to DRI=1.
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reports that rotenone-induced apoptosis does not depend directly on
inhibition of the mitochondrial respiratory chain [8,9].
We found that treatment with rotenone induces cell cycle arrest in
the G2/M phases, as previously shown [5,7]. Further, we could observe
morphological features of mitotic catastrophe, in particular the
appearanceof typical giant clusters of nuclei alongwithmicronucleation
and multinucleation [3,4]. Other observations support the idea that
rotenone induces mitotic catastrophe. Mitotic catastrophe can be
triggered upon microtubule instability leading to an abnormal mitotic
checkpoint [3,4], and rotenone binding to tubulin results in the
inhibition of the spindle assembly and thus in an anomalous spindle
checkpoint [10–13]. In addition, rotenone can induce endoreduplication
[36], a process throughwhich successive rounds of DNA replication take
place without mitosis, whichmay facilitate the polyploidization of cells
[37].
Treatment of TPC-1 cells with rotenone increased the levels of p53
together with its phosphorylation at serine 15 and its nuclear
accumulation. These three consequences are common responses to
DNA or spindle damage [24], suggesting the involvement of the protein
in rotenone-induced cell death. Cells arrested in response to spindle
assembly inhibition eventually bypass the block and exit mitosis
without an appropriate division, in a phenomenon known as mitotic
slippage [3,4,38]. Consequently, cells enter inG1with a 4 NDNA content
and this abnormality leads to the activation of the G1 checkpoint
[3,4,38]. This halt is mediated by p53 and p21 appears to be a crucial
p53-target gene in this postmitotic checkpoint [25,26].Moreover, serine
15 phosphorylation stimulates p53 transactivation and is required for
this postmitotic checkpoint [23,39]. Similarly,we observed p53 increase
and phosphorylation and upregulation of p21 following rotenone
exposure. An increase in the levels of p53 after treatment with
microtubule disruptors occurring only after tetraploid cells exit mitotic
arrest and progress to interphase was also demonstrated [26].
On the other hand, functional p53 is not an absolute requirement for
the rotenone-induced cell cycle arrest and mitotic catastrophe because
cells harboring a mutation in the DNA-binding domain of the molecule
still become arrested and display polyploidy after treatment with the
drug. This is consistent with evidence that in the absence of p53, cells
have the ability to activate alternative pathways to halt the cell cycle [3].
However, our results stress that the extensive cell death occurring after
themitotic catastrophe state is p53-dependent. Themajority of the cells
with wild-type p53 overrides the cell cycle blockage and dies after 48 h
of rotenone treatment, whereas cells with mutant p53 remain arrested
in the cell cycle in the sameperiod and do not showextensive cell death.
Kato et al. showed that the mutation present in the 8505-C cell line
(Arg248Gly) leads to a total absence of the capacity of p53 to
transactivate key players of cell death execution such as Bax, NOXA
and Apoptosis-inducing Protein 1 [40]. This may explain why 8505-C
cells are less prone to die upon treatment with rotenone.
Our results also suggest involvement of p53 in rotenone-induced
cellular senescence, a phenomenon that can occur as a consequence of
mitotic catastrophe [41–43]. We observed that when treated for a
longer period with rotenone, cells exhibit a senescent-like phenotype.
Cells possessing non-functional p53 display signiﬁcantly less senes-
cence than cells harboring the wild-type protein, suggesting that the
rotenone-induced cellular senescence occurs through a p53-pathway.
In fact, p53 and p16 are the initiators of two independent senescence
pathways [22] and we did not observe increase in the expression of
p16 (data not shown).
In summary, we show that rotenone induces a panoply of effects,
including mitotic catastrophe, mitotic slippage, cell death and cellular
senescence. Our results are in agreement with ﬁndings that rotenone
may act by at least two different pathways [5,7,8,12,13]: acting
directly on mitochondria and in the nucleus. The tumor suppressor
protein p53 is involved in these processes, especially regarding the
extensive cell death that occurs following a polyploidy state.Acknowledgments
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